228 related articles for article (PubMed ID: 16077066)
1. New drugs target hypoxia response in tumors.
Garber K
J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066
[No Abstract] [Full Text] [Related]
2. Targeting tumors through the HIF system.
Ratcliffe PJ; Pugh CW; Maxwell PH
Nat Med; 2000 Dec; 6(12):1315-6. PubMed ID: 11100107
[No Abstract] [Full Text] [Related]
3. Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.
Wilczynski J; Duechler M; Czyz M
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):301-7. PubMed ID: 21625847
[TBL] [Abstract][Full Text] [Related]
4. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor.
Lee K; Kim HM
Arch Pharm Res; 2011 Oct; 34(10):1583-5. PubMed ID: 22076756
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.
Moeller BJ; Dreher MR; Rabbani ZN; Schroeder T; Cao Y; Li CY; Dewhirst MW
Cancer Cell; 2005 Aug; 8(2):99-110. PubMed ID: 16098463
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia inducible factor 1 inhibitors for cancer therapy.
Qing L; Qing W
Minerva Chir; 2019 Oct; 74(5):442-444. PubMed ID: 31115241
[No Abstract] [Full Text] [Related]
7. [Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].
Wang JJ; Li J; Geng MY
Yao Xue Xue Bao; 2008 Jun; 43(6):565-9. PubMed ID: 18822956
[TBL] [Abstract][Full Text] [Related]
8. New checkpoint blockers begin human trials.
Garber K
J Natl Cancer Inst; 2005 Jul; 97(14):1026-8. PubMed ID: 16030295
[No Abstract] [Full Text] [Related]
9. Engaging the vascular component of the tumor response.
Fuks Z; Kolesnick R
Cancer Cell; 2005 Aug; 8(2):89-91. PubMed ID: 16098459
[TBL] [Abstract][Full Text] [Related]
10. New anticancer strategies targeting HIF-1.
Yeo EJ; Chun YS; Park JW
Biochem Pharmacol; 2004 Sep; 68(6):1061-9. PubMed ID: 15313402
[TBL] [Abstract][Full Text] [Related]
11. Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockade.
Macpherson GR; Figg WD
Cancer Biol Ther; 2004 Jun; 3(6):503-4. PubMed ID: 15197355
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia inducible factor as a cancer drug target.
Welsh SJ; Powis G
Curr Cancer Drug Targets; 2003 Dec; 3(6):391-405. PubMed ID: 14683498
[TBL] [Abstract][Full Text] [Related]
13. [Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy].
Clottes E
Bull Cancer; 2005 Feb; 92(2):119-27. PubMed ID: 15749641
[TBL] [Abstract][Full Text] [Related]
14. OSI-461 (OSI).
Galmarini CM
Curr Opin Investig Drugs; 2004 Jun; 5(6):648-56. PubMed ID: 15242254
[TBL] [Abstract][Full Text] [Related]
15. [Problems in oncologic pharmacology].
Filov VA; Gershanovich ML; Akimov MA; Akimov AA
Vopr Onkol; 1998; 44(6):651-61. PubMed ID: 10087958
[No Abstract] [Full Text] [Related]
16. Hypoxia inducible factor-1: a novel target for cancer therapy.
Belozerov VE; Van Meir EG
Anticancer Drugs; 2005 Oct; 16(9):901-9. PubMed ID: 16162966
[TBL] [Abstract][Full Text] [Related]
17. New anticancer agents.
Weiss GR; Burris 3rd HA; Eckardt JR; Eckhardt SG; Fields SM; O'Rourke T; Rodriguez GI; Rothenberg ML; Valley AJ
Cancer Chemother Biol Response Modif; 1996; 16():132-67. PubMed ID: 8639381
[No Abstract] [Full Text] [Related]
18. CC-5013 (Celgene).
Mitsiades CS; Mitsiades N
Curr Opin Investig Drugs; 2004 Jun; 5(6):635-47. PubMed ID: 15242253
[TBL] [Abstract][Full Text] [Related]
19. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
20. New sources and new antitumor drugs in development.
Weiss RB
Semin Oncol; 1997 Apr; 24(2):153-5. PubMed ID: 9129685
[No Abstract] [Full Text] [Related]
[Next] [New Search]
